6533b81ffe1ef96bd1277c72
RESEARCH PRODUCT
Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study.
Stefan BlankenbergAtherogene InvestigatorsLaurence TiretIrène Juhan-vagueEdith LubosDirk PeetzThomas MünzelRenate B. SchnabelChristoph BickelHans-jürgen RupprechtViviane NicaudPierre MorangeMarie-christine Alessisubject
Malemedicine.medical_specialtyAcute coronary syndromeTime FactorsLipoproteinsMyocardial InfarctionRisk AssessmentSeverity of Illness IndexAngina PectorisThromboplastinCoronary artery diseaseCohort StudiesTissue factor pathway inhibitorPredictive Value of TestsInternal medicineGermanymedicineHumansMyocardial infarctionProspective StudiesAgedProportional Hazards ModelsUnstable anginabusiness.industryHazard ratioCoronary StenosisHematologySyndromeMiddle Agedmedicine.diseasePrognosisThrombosisCardiovascular DiseasesCardiologyFemalebusinessBiomarkersBlood drawingFollow-Up Studiesdescription
Summary. Background: Tissue factor (TF) and its specific inhibitor, tissue factor pathway inhibitor (TFPI), are important contributors to the initiation of the coagulation process. Objectives: To compare plasma levels of soluble TF (sTF) and free-TFPI (f-TFPI) between patients with stable angina pectoris (SAP) and acute coronary syndrome (ACS) and to assess the impact of the two variables on long-term prognosis. Patients/methods: Patients with SAPs (n = 1146) and acute coronary syndrome (n = 523) from the AtheroGene study were included and followed for 2.3 years. Because of the strong impact of unfractionated heparin (UFH) on f-TFPI levels, but not on sTF levels, patients having received UFH before blood drawing were excluded from the analyses on f-TFPI (n = 226). Results: On admission, no significant differences in sTF levels were observed between SAP and ACS patients. By comparison to patients with stable angina, f-TFPI levels significantly increased in patients with acute unstable angina and further increased in patients presenting with non-ST-elevation myocardial infarction and ST-elevation myocardial infarction (P < 10−4). Among the 1669 individuals with a coronary artery disease, 56 died from a cardiovascular cause. In prospective analyses, high sTF levels were independently associated with an increased risk of cardiovascular death in individuals with ACS (fully adjusted hazard ratio associated with one quartile increase = 2.06; 95% confidence interval 1.24–3.45; P = 0.006) but not in those with SAP (hazard ratio = 1.07; 95% confidence interval 0.78–1.46; P = 0.67). In SAP and ACS patients, high f-TFPI levels were not independently associated with an increased risk of cardiovascular death. Conclusions: Plasma sTF levels were predictive of cardiovascular mortality in individuals with ACS, whereas f-TFPI levels were associated with the severity of myocardial damage on admission but were not independently related to outcome.
year | journal | country | edition | language |
---|---|---|---|---|
2007-03-01 | Journal of thrombosis and haemostasis : JTH |